Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01867866 | Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone | completed | Phase 1 | 44 | Taiho Oncology, Inc.INDUSTRY | 1 | Sep 5, 2024 | clinicaltrials |
| NCT01867879 | Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors | completed | Phase 1 | 44 | Taiho Oncology, Inc.INDUSTRY | 1 | Sep 5, 2024 | clinicaltrials |
| Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI |
| completed |
| Phase 1 |
| 46 |
| Taiho Oncology, Inc.INDUSTRY |
| 1 |
| Sep 5, 2024 |
| clinicaltrials |
| NCT02031055 | Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors | completed | Phase 1 | 8 | Taiho Oncology, Inc.INDUSTRY | 1 | Sep 5, 2024 | clinicaltrials |
| NCT02301104 | A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment | completed | Phase 1 | 24 | Taiho Oncology, Inc.INDUSTRY | 1 | Sep 5, 2024 | clinicaltrials |
| NCT02301117 | A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment | completed | Phase 1 | 43 | Taiho Oncology, Inc.INDUSTRY | 3 | Sep 5, 2024 | clinicaltrials |
| NCT02454062 | A Trial of TAS-114 in Combination With S-1 | completed | Phase 1 | 120 | Taiho Oncology, Inc.INDUSTRY | 4 | Sep 4, 2024 | clinicaltrials |
| NCT02965885 | A Study of TAS-116 in Patients With Solid Tumors | completed | Phase 1 | 31 | Taiho Oncology, Inc.INDUSTRY | 3 | Sep 4, 2024 | clinicaltrials |
| NCT04366648 | Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor | completed | Phase 1 | 25 | JenKem Technology Co., Ltd.INDUSTRY | 1 | Sep 4, 2024 | clinicaltrials |
| NCT05065710 | A Study of ZL-1211 in Patients With Advanced Solid Tumor | completed | Phase 1 | 34 | Zai Biopharmaceutical (Suzhou) Co., Ltd.INDUSTRY | 2 | Sep 3, 2024 | clinicaltrials |
| NCT06582030 | Stop Addiction Stigma | completed | N/A | 93 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT05088070 | Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors | completed | Phase 1 | 40 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Aug 30, 2024 | clinicaltrials |
| NCT03473925 | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | completed | Phase 2 | 107 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Aug 28, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT03421353 | AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer | completed | Phase 1 | 76 | AstraZenecaINDUSTRY | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05131113 | Stratification of Patients in Oncogeriatrics and Personalization of Interventions(ONKO-FRAIL) | completed | N/A | 186 | Biogipuzkoa Health Research InstituteOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT04422457 | Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients | completed | N/A | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT04770688 | Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib(AUTOMAN) | completed | Phase 1 / Phase 2 | 25 | Shanghai Chest HospitalOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT04067960 | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer | completed | Early Phase 1 | 197 | Mayo ClinicOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04121442 | Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 15 | Buzzard PharmaceuticalsINDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT00878423 | Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors | completed | Phase 1 | 62 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT00894894 | Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies | completed | Phase 1 | 22 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03852251 | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma | completed | Phase 1 / Phase 2 | 338 | AkesoINDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06172309 | A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors | completed | Phase 1 | 32 | Nanjing Chia-tai Tianqing PharmaceuticalINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03154294 | Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors | completed | Phase 1 | 19 | Avera McKennan Hospital & University Health CenterOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT04538625 | Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy(OnTARGET) | completed | Phase 3 | 287 | Napo Pharmaceuticals, Inc.INDUSTRY | 5 | Jul 26, 2024 | clinicaltrials |
| NCT01283945 | Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 134 | Institut de Recherches Internationales ServierOTHER | 3 | Jul 25, 2024 | clinicaltrials |
| NCT02846038 | Understanding Communication in Healthcare to Achieve Trust (U-CHAT) | completed | — | 138 | St. Jude Children's Research HospitalOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT04675528 | Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) FEEL Study(FEEL) | completed | Phase 1 | 25 | Daehwa Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT05702424 | Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer | completed | Phase 1 | 14 | IGM Biosciences, Inc.INDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT01855477 | CPCT-02 Biopsy Protocol(CPCT-02) | completed | N/A | 6,927 | Foundation CPCTOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT03641547 | M6620 Plus Standard Treatment in Oesophageal and Other Cancer(CHARIOT) | completed | Phase 1 | 36 | University of OxfordOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT04570839 | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | completed | Phase 1 / Phase 2 | 48 | Compugen LtdINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT01231347 | QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas(GAMMA) | completed | Phase 3 | 800 | NantCell, Inc.INDUSTRY | 32 | Jul 16, 2024 | clinicaltrials |
| NCT03320330 | Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 26 | Children's Oncology GroupNETWORK | 1 | Jul 15, 2024 | clinicaltrials |
| NCT04410224 | Study of ASN004 in Patients With Advanced Solid Tumors(ASN004) | completed | Phase 1 | 19 | Kirilys Therapeutics Inc.INDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT03802123 | ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors(iCorrelate) | completed | Phase 2 | 52 | ImaginAb, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT04505839 | First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors | completed | Phase 1 | 32 | ST Pharm Co., Ltd.INDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04532372 | Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy | completed | Phase 1 / Phase 2 | 2 | City of Hope Medical CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03934814 | Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | completed | Phase 1 | 98 | I-Mab Biopharma US LimitedINDUSTRY | 2 | Jul 1, 2024 | clinicaltrials |
| NCT04856774 | Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 81 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT04641871 | Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies | completed | Phase 1 | 78 | Symphogen A/SINDUSTRY | 4 | Jun 26, 2024 | clinicaltrials |
| NCT05594875 | A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors | completed | Phase 1 | 9 | Atridia Pty Ltd.INDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT01639950 | Validating Pain Scales in Children and Young Adults | completed | — | 252 | National Cancer Institute (NCI)NIH | 1 | Jun 21, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 5, 2024source: clinicaltrials